Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, recently released an operational update regarding the strategic initiatives of its operating segments – MINDCURE Research and MINDCURE Technology. The update detailed the company’s progress and plans for the immediate future. “As a member of the Digital Therapeutics Alliance, MINDCURE delivers digital therapeutics (‘DTx’) that are evidence-based interventions driven by high-quality software to prevent, manage and treat medical disorders,” reads a recent article. A leader in advanced proprietary technology and research centered around psychedelics, MINDCURE is currently advancing multiple programs and products to this end. “MINDCURE Research included updates on both The Desire Project and Ibogaine… MINDCURE Technology also released an update on its DTx technology, iSTRYM, and its release as a minimum viable product (‘MVP’) into partner clinics across North America. MINDCURE’s unique and diversified approach works with multiple touchpoints, including technology, research, and drug supply and partnerships.”
To view the full article, visit https://ibn.fm/JIsgx
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
